Z-13752A is a mercaptopropanoyl amino acid. Z-13752A inhibits NEP and ACE, with Ki values of 1.8 and 3.2 nM, respectively. Z-13752A decreases the arterial blood pressure and increases coronary blood flow. Z-13752A can be used in the research of coronary artery occlusion.

Tubulin/VEGFR-2-IN-2 is an orally active tubulin and VEGFR-2 inhibitor with IC50s of 3.27 and 0.09 μM, respectively. Tubulin/VEGFR-2-IN-2 exerts the antitumor effects through multifaceted pathways, including enhancing reactive oxygen species (ROS) generation, disrupting mitochondrial membrane potential, inducing apoptosis, and arresting the cell cycle. Tubulin/VEGFR-2-IN-2 demonstrates anti-angiogenic properties by significantly impairing endothelial cell migration, invasion, and tube formation in vitro. Tubulin/VEGFR-2-IN-2 suppresses angiogenesis, tumor growth, and metastasis in vivo. Tubulin/VEGFR-2-IN-2 can be used for non-small lung cancer, breast cancer, gastric cancer and lymphoma.

IL-17-IN-6 is a IL-17 inhibitor with a pIC50 of 7.6 against human targets. IL-17-IN-6 binds to IL-17A and blocks downstream pro-inflammatory signaling pathways. IL-17-IN-6 inhibits the release of IL-6 from normal human skin fibroblasts stimulated by IL-17A and TNF. IL-17-IN-6 can be used for research on inflammatory and autoimmune diseases.

1,2-Olein-3-acetyl is an acylglycerol.

MRS8454 is a positive allosteric modulator (PAM) of the A3 adenosine receptor (A3AR). MRS8454 can significantly enhance the maximum effect of the standard agonist Cl-IB-MECA by approximately 286%-300%, and significantly reduce its EC50 value. MRS8454 effectively enhances the ability of A3AR agonists to inhibit the cAMP accumulation induced by Forskolin. MRS8454 can be used for the development of molecular probes.

Zaladenant is an adenosine receptor antagonist with antitumor effects.

Neladenoson is a potent and selective Adenosine A1 Receptor agonist. EGFR-IN-162 is promising for research of heart failure.

I-AB-MECA is an important radioligand for the study of A3 adenosine receptors (A3AR).

CP-66713 is a selective adenosine A2 receptor antagonist, with Ki of 22 nM. CP-66713 inhibits induction of long-term potentiation of evoked synaptic potentials. CP-66713 can be used in the study of neurological diseases.

CGH 2466 dihydrochloride is an orally active adenosine A1, A2B and A3 receptor antagonist with the IC50 values of 19 nM, 21 nM, and 80 nM respectively. CGH 2466 dihydrochloride inhibits p38 MAPK (IC50 = 187~ 400 nM) and phosphodiesterase type 4D (IC50 = 22 nM). CGH 2466 dihydrochloride displays potent anti-inflammatory effects both in vitro and in vivo, and can be used for research on asthma and chronic obstructive pulmonary disease (COPD).

Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research.

QAF-805 (QAF805) is a potent, dual adenosine-A2B receptor and adenosine-A3 receptor antagonist with Ki of 3.4 nM (A2B).

TRR469 is a potent, selective adenosine A1 receptor (A1AR) positive allosteric modulator with pKb of 5.36, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice.

OT-7999 (OT7999) is a potent and selective adenosine A3 receptor antagonist with Ki of 0.61 nM (human A3 receptor) in radioligand binding assays.

MRS7935 is a potent, selective positive allosteric modulator (PAM) of A1 adenosine receptor (A1AR) with EC50 of 1.43 uM.

KF-26777 (KF26777) is a potent and selective adenosine A3 receptor antagonist with Ki of 0.2 nM (human A3 receptor).

I-ABOPX (BW-A522) is a potent, selective A3 adenosine receptor antagonist with high affinity for both the ovine (Ki=3 nM) and human (Ki=19 nM) A3 receptors.

BnOCPA is a potent and powerful analgesic and a highly selective and potent, full agonist at human adenosine A1 receptors (A1Rs) with pEC50 of 7.23 in a NanoBRET agonist binding assay.

2'-MeCCPA is a potent and selective A1 adenosine receptors (A1AR) agonist. 2'-MeCCPA efficiently inhibits cAMP modulation in both direct pathway medium spiny neurons (dMSNs) and indirect pathway medium spiny neurons (iMSNs).

CGS 21680 hydrochloride is an A2A adenosine receptor agonist (Ki = 27 nM).

CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;

ANR-94 is a potent and selective adenosine A2A receptor (AA2AR) antagonist with an Ki of 46 nM for hAA2AR. ANR 94 has the potential for the research of Parkinson's disease.

PSB11 hydrochloride is an antagonist with reverse excitatory activity for human A3 Adenosine Receptor with high affinity (Ki=2.3 nM).

ZM 241385 is a Potent A2 adenosine receptor antagonist, with approx 50-fold selectivity for A2A receptors.

Vipadenant(BIIB-014) is an adenosine A2a antagonist with Ki of 1.3 nM; less potent for A1(Ki=69 nM).

Preladenant(SCH 420814) is a potent and selective antagonist at the adenosine A2A receptor.

Istradefylline(KW6002) is a very potent, selective and orally active adenosine A2A receptor antagonist(Ki=2.2 nM) in experimental models of Parkinson's disease.

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.

AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.

AB928 is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist with immunomodulatory activity.